Skip to main content

Table 1 Association between AHNAK and clinicopathological characteristics in triple-negative breast cancer

From: AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer

Variables Cases Ahnak P value
(n = 221) high No. (%) low No. (%)
Age (years)       0.586
 <50 133 66 49.6% 67 50.4%  
 ≥50 88 47 53.4% 41 46.6%  
Menopause       0.338
 yes 90 50 55.6% 40 44.4%  
 no 131 63 48.1% 68 51.9%  
 BMI       0.156
 <25 169 91 53.8% 78 46.2%  
 ≥25 52 22 42.3% 30 57.7%  
Tumor status (T)       0.015*
 T1 67 42 62.7% 25 37.3%  
 T2 120 61 50.8% 59 49.2%  
 T3 17 6 35.3% 11 64.7%  
 T4 17 4 23.5% 13 76.5%  
Lymph node status (N)       <0.001*
 N0 117 80 68.4% 37 31.6%  
 N1 57 21 36.8% 36 63.2%  
 N2 35 9 25.7% 26 74.3%  
 N3 12 3 25.0% 9 75.0%  
Histological grade       0.139
 G1 + G2 108 61 56.5% 47 43.5%  
 G3 113 52 46.0% 61 54.0%  
LN infiltration       <0.001*
 No 117 80 68.4% 37 31.6%  
 Yes 104 33 31.7% 71 68.3%  
TNM stage       <0.001*
 I 48 34 70.8% 14 29.2%  
 II 111 64 57.7% 47 42.3%  
 III 56 14 25.0% 42 75.0%  
 IV 6 1 16.7% 5 83.3%  
  1. Abbreviation: BMI body mass index, LN lymph node
  2. *P < 0.05, statistically significant